GlaxoSmithKline halts Excedrin production over manufacturing stumble

GlaxoSmithKline, in the midst of sorting out its massive consumer health venture with Pfizer, has run into issues with one of its best-selling consumer brands. It has voluntarily halted production and distribution of Excedrin after manufacturing issues put the quality of some of the pain meds into question.